Humira

Botox Maker Allergan Sold to AbbVie for $63B
M&A

Botox Maker Allergan Sold to AbbVie for $63B

AbbVie faces pressure to diversify its portfolio as Humira, the world’s best-selling drug, faces increased competition from cheaper versions in Europe.
By Lauren Muskett | June 25, 2019
Read More
Treasury Stance Regardless, Another Tax-Inversion Deal Pops Up
Tax

Treasury Stance Regardless, Another Tax-Inversion Deal Pops Up

AbbVie's plans to pay less taxes by relocating to Britain after buying Shire touches a raw nerve in Washington.
By Iris Dorbian | July 19, 2014
Read More